Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators

Area of Science:

• Vaccinology
• Immunology
• Nanotechnology

Background:

• Cancer peptide vaccines aim to stimulate host immunity against tumors but face challenges due to limited antigen immunogenicity.
• Enhancing peptide antigen potency is crucial for effective cancer vaccine development, particularly for metastatic disease and recurrence prevention.
• Self-adjuvanting vaccines, created by conjugating antigens with adjuvants, offer a promising strategy to overcome these limitations.

Purpose of the Study:

• To develop an improved self-adjuvanting vaccine platform by conjugating the antigenic CH401 peptide with the adjuvant Pam3CSK4.
• To formulate these conjugates into cationic lipid nanoparticles (LNPs) smaller than 100 nm for enhanced immune cell uptake.
• To investigate the potential of supplemental adjuvants for modulating immune responses within the LNP formulation.

Main Methods:

• Conjugation of the CH401 peptide antigen with the Pam3CSK4 adjuvant.
• Formulation of antigen-adjuvant conjugates into cationic lipid nanoparticles (LNPs) using a microflow device (iLiNP) for precise size control (<100 nm).
• Incorporation of supplemental adjuvants to modulate immune responses.
• Evaluation of vaccine immunogenicity and immune response modulation in humanized mouse models.

Main Results:

• The developed vaccine candidates demonstrated significantly enhanced immunogenicity compared to conventional approaches.
• The platform enabled precise, antigen-specific modulation of immune responses.
• The cationic lipid nanoparticles facilitated efficient uptake by immune cells.
• Potent immune responses were successfully elicited in humanized mouse models.

Conclusions:

• This strategy represents a next-generation self-adjuvanting vaccine platform.
• The platform effectively enhances and fine-tunes antigen-specific immune responses.
• This innovative approach holds significant promise for the development of advanced cancer vaccines.